GlaxoSmithKline's latest makeover includes auctioning off dermatology, adding new tech and layoffs. But how many?
GSK execs announced Wednesday morning that they are setting up a 2-year program to prepare the company for its split in two — consumer healthcare and the R&D-focused outfit she and research chief Hal Barron promised to revamp and reenergize 2 years ago.
A key part of that effort is a new R&D reorganization in which the vaccines group — traditionally separate inside the global organization — will integrate its work with the pharma teams in order to orchestrate common research themes on both sides. And GSK is helping pay for the 2-year program with a plan to sell off non-core assets, starting with its dermatology drugs portfolio.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,600+ biopharma pros reading Endpoints daily — and it's free.